


# Praise u

SMART EARLY DETECTION OF PROSTATE CANCER



# Estimated mortality by country (2020)- comparison with EU27



# Impact of screening de-escalation in USA


Screening rates started declining since 2008

prostate cancer incidence rates declined 6.5% per year from 2007

Statistically significant 6.6% rise in distant stage disease in 2011-14

Mortality decline slowed down and then labelled off in white men after 2013

***In Germany primarily diagnosed locally advanced disease (cT3) increased from 29% in 2008 to 49% in 2017***






Every man in the EU needs to be **aware** of the pros and cons of **early detection for PCa**.



EU member states should be able to offer **high quality clinical standards** including state-of-the-art **individualized** approaches to achieve timely PCa detection in men who can benefit from **early treatment**.




With increasing knowledge, awareness of the need for the early detection of significant PCa, as well as societal and patient-empowerment, we envision this **algorithm** of testing will ensure **harmonization** and **cost-effective** implementation across EU member states in order to achieve the highest **decrease in mortality**, while **avoiding opportunistic testing, overdiagnosis** and **overtreatment**.



In addition to a decrease in disease specific mortality, this will **decrease the incidence and burden** of metastatic disease, and at the same time maintain and **increase quality of life** (QoL) of patients and their families, thereby resulting in improved prognosis of men diagnosed with PCa in the future.



Get insights and **assess needs** in EU member states **to design** a diagnostic strategy and algorithm for EU Prostate Cancer Screening that is **cost-effective** and be able to **raise awareness** of PCa and its implications.




EU member states **tailored recommendations** on screening strategies will be based on available knowledge on specific risk groups, a multi-step **risk-based early detection strategy** including individualized interval for PSA testing combined with risk calculators and imaging modalities, such as multiparametric magnetic resonance imaging (mpMRI).



This will allow for an approach **avoiding** unnecessary (repeated) testing, **overdiagnosis**, and consequently reducing **overtreatment** as well as the number of men diagnosed with metastatic disease and mortality.



# Work Packages



## Year 1:

In all 27 EU member states:  
needs assessment and  
state of play

## Year 2:

In 5 sites: pilot-site specific  
study protocols

## Year 3:

Detailed evaluation.

**-> Living knowledge platform on PCa screening**

# Consortium of 25 institutions from 12 Member States

## BENEFICIARIES

## ASSOCIATED PARTNERS

Erasmus MC



UMC Utrecht



International Agency  
for Research on Cancer



**EUROPA UOMO**

The Voice of Men with Prostate Cancer in Europe



XUNTA DE GALICIA  
CONSELLERÍA DE SANIDADE



REGION  
VÄSTRA GÖTALAND



NARODOWY  
INSTYTUT  
ZDROWIA  
PUBLICZNEGO  
PAŃSTWOWY INSTYTUT  
BADAWCZY




Wonca  
World family doctors. Caring for people.  
EUROPE



Karolinska  
Institutet  
KAROLINSKA  
UNIVERSITETSSJUKHUSET  
Karolinska Comprehensive Cancer Center




-  Implementation pilot sites
-  Knowledge sharing and advisory pilot sites
-  Both





# Project Deliverables

<b>WP1</b>	<b>D1</b>	<b>Project management plans</b>	<b>31 May 2023</b>
<b>WP1</b>	<b>D2</b>	<b>Quality assurance and risk mitigation plan</b>	<b>30 Sep 2023</b>
<b>WP2</b>	<b>D3</b>	<b>Needs assessment report</b>	<b>30 Nov 2023</b>
<b>WP2</b>	<b>D4</b>	<b>Living document on harm/benefit and cost effectiveness</b>	<b>30 Nov 2023</b>
<b>WP2</b>	<b>D5</b>	<b>Key Performance Indicators for PCa screening effectiveness</b>	<b>31 Mar 2024</b>
<b>WP3</b>	<b>D6</b>	<b>Capacity Assessment Report including current standard of care</b>	<b>31 Dec 2023</b>
<b>WP3</b>	<b>D7</b>	<b>Framework or protocol for implementation of PCa screening programme</b>	<b>31 Mar 2024</b>
<b>WP3</b>	<b>D8</b>	<b>Readiness and capacity assessment for sustainability and scaling report</b>	<b>31 Mar 2026</b>
<b>WP4</b>	<b>D9</b>	<b>Pilot local implementation plan (including ethical approval and data sharing agreements)</b>	<b>31 May 2024</b>
<b>WP4</b>	<b>D10</b>	<b>Pilot final report</b>	<b>30 Sep 2025</b>
<b>WP5</b>	<b>D11</b>	<b>Report on identification and participation, risk stratification for biopsy, biopsy rates, and cancer detection and opportunistic testing</b>	<b>31 Dec 2025</b>
<b>WP5</b>	<b>D12</b>	<b>Report on psychosocial aspects</b>	<b>31 Mar 2026</b>
<b>WP5</b>	<b>D13</b>	<b>Costs analysis</b>	<b>31 Mar 2026</b>
<b>WP6</b>	<b>D14</b>	<b>PRAISE-U dissemination and communication strategy</b>	<b>31 Aug 2023</b>
<b>WP6</b>	<b>D15</b>	<b>Final report on PRAISE-U dissemination and communication strategy</b>	<b>31 Mar 2026</b>



The screenshot shows an email invitation from Praise u. At the top is the Praise u logo and a graphic of a map of Europe composed of blue dots and lines. Below the graphic, the text reads: "You are invited to participate in our survey. This survey aims to identify barriers to screening for prostate cancer across the European Union as part of the Smart Early Detection in Prostate Cancer (PRAISE-U) project. Your participation will contribute to the development of early detection protocols for prostate cancer." At the bottom of the email is a dark blue button with the text "Take the Survey" in white.

**Praise u**  
SMART EARLY DETECTION OF PROSTATE CANCER

You are invited to participate in our survey. This survey aims to identify barriers to screening for prostate cancer across the European Union as part of the Smart Early Detection in Prostate Cancer (PRAISE-U) project.

Your participation will contribute to the development of early detection protocols for prostate cancer.

[Take the Survey](#)

**If you have experience of Prostate Cancer early detection, please take the survey. It will be available in all 27 EU languages very soon.**




**Share the survey with your network**

# SCAN



**Time to complete:**  
≈15 mins



**Password:**  
praise\_U



**Multiple languages**  
available

[https://uroweb.org/  
praise-u/survey](https://uroweb.org/praise-u/survey)

# Praise u

SMART EARLY DETECTION OF PROSTATE CANCER